(Q51787337)

12 April 2018

editorial

0 references

title

Therapeutic targeting of NF-κB in myelodysplastic syndromes and acute myeloid leukaemia - the biological heterogeneity. (English)

1 reference

12 April 2018

0 references

1 reference

Øystein Bruserud

1

1 reference

12 April 2018

Håkon Reikvam

series ordinal

2

1 reference

12 April 2018

language of work or name

English

0 references

publication date

1 November 2010

1 reference

12 April 2018

Expert Opinion on Therapeutic Targets

published in

1 reference

12 April 2018

volume

14

1 reference

12 April 2018

issue

11

1 reference

12 April 2018

page(s)

1139-1142

1 reference

12 April 2018

Acute myeloid leukemia: the challenge of capturing disease variety

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.525021

NF-κB as a potential therapeutic target in myelodysplastic syndromes and acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.525021

A cell initiating human acute myeloid leukaemia after transplantation into SCID mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.525021

MDS: a stem cell disorder--but what exactly is wrong with the primitive hematopoietic cells in this disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.525021

Nuclear factor-kappaB signaling: a contributor in leukemogenesis and a target for pharmacological intervention in human acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.525021

New strategies in the treatment of acute myelogenous leukemia (AML): in vitro culture of aml cells--the present use in experimental studies and the possible importance for future therapeutic approaches.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.525021

Subclassification of patients with acute myelogenous leukemia based on chemokine responsiveness and constitutive chemokine release by their leukemic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.525021

The protein kinase C agonist PEP005 increases NF-kappaB expression, induces differentiation and increases constitutive chemokine release by primary acute myeloid leukaemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.525021

The protein kinase C agonist PEP005 (ingenol 3-angelate) in the treatment of human cancer: a balance between efficacy and toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.525021

The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.525021

The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.525021

Antiangiogenic therapy in acute myelogenous leukemia: targeting of vascular endothelial growth factor and interleukin 8 as possible antileukemic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.525021

Targeting the angiopoietin (Ang)/Tie-2 pathway in the crosstalk between acute myeloid leukaemia and endothelial cells: studies of Tie-2 blocking antibodies, exogenous Ang-2 and inhibition of constitutive agonistic Ang-1 release.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.525021

10.1517/14728222.2010.525021

21 January 2018

Identifiers

DOI

1 reference

12 April 2018

1 reference

12 April 2018